logo
Plus   Neg
Share
Email

Roche Reports Positive Data From OCREVUS Phase III Open-label Extension Studies

Roche (RHHBY.PK) said data from three phase III open-label extension studies demonstrated that patients who were treated with OCREVUS for six years or more had reduced risk of disability progression in relapsing multiple sclerosis and primary progressive multiple sclerosis. The company said the results show earlier treatment with OCREVUS reduced the risk of disability progression and the effect was sustained over time.

OCREVUS is the first and only therapy approved for both relapsing multiple sclerosis and primary progressive multiple sclerosis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT